SLIGRL-NH2;(Synonyms: Protease-Activated Receptor-2 Activating Peptide) 纯度: 99.66%
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) 是一种蛋白酶激活受体-2 (PAR-2) 激动剂。

SLIGRL-NH2 Chemical Structure
CAS No. : 171436-38-7
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10;mM;*;1 mL in DMSO | ¥3179 | In-stock | |
1 mg | ¥800 | In-stock | |
5 mg | ¥2200 | In-stock | |
10 mg | ¥3900 | In-stock | |
50 mg | ; | 询价 | ; |
100 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
SLIGRL-NH2 相关产品
bull;相关化合物库:
- Bioactive Compound Library Plus
- GPCR/G Protein Compound Library
- Immunology/Inflammation Compound Library
- Peptide Library
生物活性 |
SLIGRL-NH2 (Protease-Activated Receptor-2 Activating Peptide) is an agonist of Protease-Activated Receptor-2 (PAR-2)[1]. |
IC50 Target |
PAR-2[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
SLIGRL-NH2 is an agonist of PAR-2 and MrgprC11[1]. SLIGRL-NH2 causes an L-NAME-inhibited relaxation. Based on SLIGRL-NH2 causing a concentration-dependent relaxation with an EC50 of 10 µM in endothelium-free preparations in the presence of perivascular adipose tissue (PVAT) , 20 µM is used as a suitable ‘test’ concentration of peptide in subsequent experiments designed to evaluate the effects of potential inhibitors of ADRF release/action. In the endothelium-free aorta preparations, SLIGRL-NH2 causes a concentration-dependent relaxation in preparations only in the presence of PVAT [+PVAT, -ENDO (endothelium)][2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
656.82 |
||||||||||||||||
Formula |
C29H56N10O7 |
||||||||||||||||
CAS 号 |
171436-38-7 |
||||||||||||||||
Sequence |
Ser-Leu-Ile-Gly-Arg-Leu-NH2 |
||||||||||||||||
Sequence Shortening |
SLIGRL-NH2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:;
H2O : 110 mg/mL (167.47 mM; Need ultrasonic) DMSO : 100 mg/mL (152.25 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|